These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9800740)

  • 21. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
    Raoul JL; Guyader D; Bretagne JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
    J Nucl Med; 1994 Nov; 35(11):1782-7. PubMed ID: 7525901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
    Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
    Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
    Chow PK
    Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
    Manesis EK; Giannoulis G; Zoumboulis P; Vafiadou I; Hadziyannis SJ
    Hepatology; 1995 Jun; 21(6):1535-42. PubMed ID: 7768497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
    Treiber G; Röcken C; Wex T; Malfertheiner P
    Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
    Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
    J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
    Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma.
    Martínez Cerezo FJ; Tomás A; Donoso L; Enríquez J; Guarner C; Balanzó J; Martínez Nogueras A; Vilardell F
    J Hepatol; 1994 Jun; 20(6):702-6. PubMed ID: 7930468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
    Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen.
    Farinati F; Salvagnini M; de Maria N; Fornasiero A; Chiaramonte M; Rossaro L; Naccarato R
    J Hepatol; 1990 Nov; 11(3):297-301. PubMed ID: 1705274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.
    Li X; Dong M; Lin Q; Chen ZH; Ma XK; Xing YF; Wan XB; Wen JY; Wei L; Chen J; Wu XY
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):86-92. PubMed ID: 23279888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma.
    Melia WM; Johnson PJ; Williams R
    Cancer Treat Rep; 1987 Dec; 71(12):1213-6. PubMed ID: 2446752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
    Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
    Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruptured primary hepatocellular carcinoma at Chulalongkorn University Hospital: a retrospective study of 32 cases.
    Pawarode A; Voravud N
    J Med Assoc Thai; 1997 Nov; 80(11):706-14. PubMed ID: 9385767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
    Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
    Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.